Search results
Nov 7, 2023 · 23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’. 23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more. Published Nov. 7, 2023. By Alexandra Pecci.
Nov 7, 2023 · CEO Anne Wojcicki on turning 23andMe into a ‘full-fledged biotech’. 23andMe always had larger aims than at-home genetics testing. In this in-depth interview, Wojcicki explains the company’s foray into drug R&D. Anne Wojcicki attends a 2019 event at the Wallis Annenberg Center for the Performing Arts in Los Angeles.
Apr 29, 2022 · Anne Wojcicki, Co-Founder of 23andMe: Making Her Own Way. Post grad, Wojcicki began working as a healthcare consultant at Passport Capital and at Investor AB. Passport Capital is an investment fund based in San Francisco. For four years, she worked as a healthcare investment analyst.
Dec 1, 2021 · 23andMe’s shares are down 35% since the merger, leaving a big dent in the fortune of the company’s largest shareholder, cofounder and CEO Anne Wojcicki. The 48-year-old entrepreneur became a ...
Dec 2, 2021 · The deal left Wojcicki holding about 99 million publicly-traded shares worth $13.32 each by the end of their first day of trading—putting her stake at more than $1.3 billion.
“Anne is a true innovator in so many ways for being one of the first digital health technology pioneers, and for thoughtfully creating a business model based on prevention, rather than treatment after the problem has already manifested itself as a disease,” Makower said, adding that Wojcicki’s talk fit within the broader strategy of the ...
Shared by Anne Wojcicki. Experience: 23andMe · Location: Mountain View · 500+ connections on LinkedIn. View Anne Wojcicki’s profile on LinkedIn, a professional community of 1 billion members.
- 23andMe
